製品名:2-fluoro-9H-purin-6-amine

IUPAC Name:2-fluoro-9H-purin-6-amine

CAS番号:700-49-2
分子式:C5H4FN5
純度:98%
カタログ番号:CM112176
分子量:153.12

包装単位 有効在庫 価格(USD) 数量
CM112176-5g in stock ƃǫ
CM112176-10g in stock ŪȖƛ
CM112176-25g in stock ǫǑŪ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:700-49-2
分子式:C5H4FN5
融点:-
SMILESコード:NC1=C2N=CNC2=NC(F)=N1
密度:
カタログ番号:CM112176
分子量:153.12
沸点:676.9°C at 760 mmHg
MDL番号:MFCD01632749
保管方法:Keep in a tight container and store at ambient temperature

Category Infos

Purines
Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
purine wholesale
Find trusted purine wholesaler. Any requirements and problems can ask us at any time.

Column Infos

Islatravir and Lenacapavir
Gilead and Merck announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class , long-acting HIV capsid inhibitor. At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study. Results of the primary endpoint (HIV-1 RNA ≥50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24;the participant later suppressed on islatravir and lenacapavir at Week 30.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.